Join
Live feed
·
PRReleasevia Quantisnow
Nexalin Technology Inc. logo

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

ByQuantisnow·Wall Street's wire, on your screen.
NXL· Nexalin Technology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXL (Nexalin Technology Inc.) and more on Quantisnow.